Your AI-Trained Oncology Knowledge Connection!
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the antibody-drug conjugate polatuzumab vedotin for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for a hematopoietic stem cell transplant.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the combination of lenalidomide and rituximab for the treatment of adult patients with grade 1 to 3a previously treated follicular lymphoma.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease (breast and/or lymph nodes) following neoadjuvant taxane-based chemotherapy and HER2-targeted therapy.
The FDA has granted an accelerated approval to zanubrutinib capsules for the treatment of adult patients with mantle cell lymphoma who have received ≥1 prior therapy.
Mark G. Kris, MD, discusses the impact of targeted therapy in patients with EGFR-mutant NSCLC and the encouraging activity that has been reported with checkpoint inhibitors in advanced squamous disease.
Secondary cytoreduction followed by chemotherapy was not found to improve overall survival compared with chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.
Tiffany A. Traina, MD, discusses emerging therapies for the management of metastatic triple-negative breast cancer.
Ashwani Rajput, MD, a cancer surgeon and researcher with a special interest in health care disparities, has been appointed director of the Kimmel Cancer Center at Johns Hopkins for the Washington, DC, region.
The Association of Community Cancer Centers (ACCC) 2019 Clinical Research Award was presented to Ethan Basch, MD, MSc, Director, Cancer Outcomes Research Program, and Professor, Hematology and Oncology, UNC, Lineberger Comprehensive Cancer Center. The award was presented during the ACCC 36th National Oncology Conference in Orlando, Florida.
Isabel Preeshagul, DO, MBS, discusses encouraging updates with molecular drivers in non–small cell lung cancer and her advice to community oncologists treating patients.
Erik P. Castle, MD, discusses the role of cytoreductive nephrectomy in renal cell carcinoma based on interpretation of the CARMENA trial results.
Erika P. Hamilton, MD, discussed several studies in the HER2-positive breast cancer space and the sequencing challenges that have emerged.
Treatment with the selective ROCK2 inhibitor KD025 led to statistically significant overall response rates in patients with chronic graft-versus-host disease who have received ≥2 prior lines of systemic therapy.
The 2019 ACCC Annual Achievement Award was presented posthumously to Arti Hurria, MD, FASCO, City of Hope.
Thai H. Ho, MD, PhD, discusses frontline treatment considerations in metastatic renal cell carcinoma, the utility of TKI monotherapy, and new combinations on the horizon.
Komal Jhaveri, MD, FACP, discusses updates in research for metastatic HR-positive, HER2-negative breast cancer.
Varlitinib combined with capecitabine did not improve progression-free survival nor overall response rate compared with capecitabine/placebo as a second-line treatment in patients with biliary tract cancer.
The use of immunotherapy, either as monotherapy or in combination with chemotherapy, continues to raise the bar with regard to overall survival benefit in patients with newly diagnosed, advanced nonsquamous non–small cell lung cancer.
The FDA has granted a priority review designation to a supplemental biologics license application for the combination of nivolumab and ipilimumab for the treatment of patients with advanced hepatocellular carcinoma who received prior therapy with sorafenib.
Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.
Andreas Kaubisch, MD, sheds light on systemic therapies available in liver cancer and some of the practice-changing phase III trials that have read out in the space.
Phillip J. Koo, MD, discusses the use of conventional imaging as well as the next-generation imaging tools that have the potential to change the management of patients with recurrent prostate cancer.
Joshua M. Lawrenz, MD, discusses the use of hypofractionated radiotherapy versus conventional radiotherapy in soft tissue sarcoma.
Avelumab did not improve overall survival as frontline maintenance following induction chemotherapy in patients with unresectable, locally advanced, or metastatic HER2-negative gastric or gastroesophageal junction cancer.
The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
A supplemental new drug application has been submitted to the FDA for ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) for the first-line treatment of patients ≤70 years old with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Michael D. Offin, MD, discusses ongoing research focusing on some of the less-common targetable mutations in non–small cell lung cancer.
The ACCC David King Community Clinical Scientist Award was awarded to Paul D. Hansen, MD, FACS, a pioneering leader in research on minimally invasive approaches to major liver and pancreas surgery and the promise these techniques hold for improving the quality of care, the patient experience, and potentially reducing healthcare costs.
The phase I/II CIRLL study, which is evaluating the combination of the monoclonal antibody cirmtuzumab (UC-961) plus ibrutinib has opened an expansion cohort to include patients with mantle cell lymphoma.
Three game-changing immunotherapy trials have transformed the treatment paradigm in frontline clear cell renal cell carcinoma. At the 37th Annual CFS®, Robert J. Motzer, MD, compared the findings from the three studies.